Perlecan: A Potential Target for Pancreatic Cancer Treatment

Understanding Pancreatic Cancer

Pancreatic cancer is a highly aggressive disease, associated with a dismal survival rate of only 7% at five years following diagnosis. It ranks among the leading causes of cancer-related mortality. Current treatment options yield an average survival of less than one year, primarily due to the lack of early signs and symptoms. By the time patients receive a diagnosis, the cancer has often metastasized to other areas of the body. This grim outlook underscores the urgent need for innovative therapeutic strategies.

Recent Research Findings

A recent study published in *Nature Communications* has shed light on the mechanisms through which pancreatic cancer tumors spread. Conducted by a collaborative team of scientists from Australia, the United States, and the United Kingdom, the research utilized mouse models to explore the role of cancer-associated fibroblasts in tumor progression.

The study revealed that cancer cells harboring mutations in the p53 gene can effectively “educate” surrounding fibroblasts to create a supportive microenvironment that promotes cancer spread. This interaction allows even a small number of aggressive cancer cells to enhance the dissemination of less aggressive cells. Furthermore, the aggressive cancer cells can manipulate and remodel surrounding tissues, providing a protective barrier against chemotherapy.

The Role of Perlecan

One significant finding from the study is the identification of perlecan, a molecule produced by these cancer cells, as a key player in this process. The researchers investigated pancreatic cancer mouse models where the levels of perlecan were reduced. They observed that this reduction not only curbed cancer spread but also improved the tumor’s sensitivity to chemotherapy.

Implications for Future Treatments

These insights point to potential new therapeutic targets for pancreatic cancer treatment. Traditionally, cancer therapies have primarily focused on targeting the cancer cells themselves, with limited attention given to the tumor microenvironment. By targeting perlecan and similar molecules in the tumor’s surroundings, there may be a promising avenue for enhancing treatment effectiveness for pancreatic cancer and potentially other cancers, such as prostate and breast cancer.

Conclusion

The findings of this research highlight the importance of understanding the tumor microenvironment in developing more effective therapies for pancreatic cancer. As the scientific community continues to explore these new targets, there is hope for improved outcomes for patients facing this challenging disease.

References

Vennin, C., Mélénec, P., Rouet, R., Nobis, M., Cazet, A. S., Murphy, K. J., . . . Timpson, P. (2019). CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. *Nature Communications, 10*(1). doi:10.1038/s41467-019-10968-6

Key to targeting the spread of pancreatic cancer. (2019, August 12). Retrieved from https://www.eurekalert.org/pub_releases/2019-08/giom-ktt080719.php

Image credit: Max Nobis